دورية أكاديمية
Prediagnostic Prescription Antibiotics Use and Survival in Patients with Colorectal Cancer: A Swedish National Register-Based Study.
| العنوان: | Prediagnostic Prescription Antibiotics Use and Survival in Patients with Colorectal Cancer: A Swedish National Register-Based Study. |
|---|---|
| المؤلفون: | Lu SSM; Department of Radiation Sciences, Oncology unit, Umeå University, Umeå, Sweden., Rutegård M; Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden.; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden., Ahmed M; Department of Radiation Sciences, Oncology unit, Umeå University, Umeå, Sweden., Häggström C; Department of Public Health and Clinical Medicine, Registry Centre North, Umeå University, Umeå, Sweden., Gylfe Å; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.; Umeå Centre for Microbial Research, Umeå University, Umeå, Sweden.; Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden., Harlid S; Department of Radiation Sciences, Oncology unit, Umeå University, Umeå, Sweden., Van Guelpen B; Department of Radiation Sciences, Oncology unit, Umeå University, Umeå, Sweden.; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden. |
| المصدر: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2023 Oct 02; Vol. 32 (10), pp. 1391-1401. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print Cited Medium: Internet ISSN: 1538-7755 (Electronic) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991- |
| مواضيع طبية MeSH: | Anti-Bacterial Agents*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/epidemiology , Colorectal Neoplasms*/diagnosis, Humans ; Cohort Studies ; Sweden/epidemiology ; Data Collection |
| مستخلص: | Background: Antibiotics use is associated with higher colorectal cancer risk, but little is known regarding any potential effects on survival. Methods: We conducted a nationwide cohort study, using complete-population data from Swedish national registers between 2005 and 2020, to investigate prediagnostic prescription antibiotics use in relation to survival in colorectal cancer patients. Results: We identified 36,061 stage I-III and 11,242 stage IV colorectal cancer cases diagnosed between 2010 and 2019. For stage I-III, any antibiotics use (binary yes/no variable) was not associated with overall or cancer-specific survival. Compared with no use, moderate antibiotics use (total 11-60 days) was associated with slightly better cancer-specific survival [adjusted HR (aHR) = 0.93; 95% confidence interval (CI), 0.86-0.99)], whereas very high use (>180 days) was associated with worse survival [overall survival (OS) aHR = 1.42; 95% CI, 1.26-1.60, cancer-specific survival aHR = 1.31; 95% CI, 1.10-1.55]. In analyses by different antibiotic types, although not statistically significant, worse survival outcomes were generally observed across several antibiotics, particularly macrolides and/or lincosamides. In stage IV colorectal cancer, inverse relationships between antibiotics use and survival were noted. Conclusions: Overall, our findings do not support any substantial detrimental effects of prediagnostic prescription antibiotics use on cancer-specific survival after colorectal cancer diagnosis, with the possible exception of very high use in stage I-III colorectal cancer. Further investigation is warranted to confirm and understand these results. Impact: Although the study findings require confirmation, physicians probably do not need to factor in prediagnostic prescription antibiotics use in prognosticating patients with colorectal cancer. (©2023 The Authors; Published by the American Association for Cancer Research.) |
| References: | Int J Cancer. 2018 Jan 15;142(2):238-250. (PMID: 28921583) Br J Cancer. 2020 Dec;123(12):1825-1832. (PMID: 32968205) J Cancer. 2020 Jun 28;11(17):5135-5149. (PMID: 32742461) Br J Surg. 2018 Jan;105(2):e131-e141. (PMID: 29341151) PM R. 2019 Oct;11(10):1132-1134. (PMID: 31359609) Gut. 2019 Nov;68(11):1971-1978. (PMID: 31427405) BMC Public Health. 2011 Jun 09;11:450. (PMID: 21658213) J Natl Cancer Inst. 2022 Jan 11;114(1):38-46. (PMID: 34467395) Nat Hum Behav. 2018 Jan;2(1):6-10. (PMID: 30980045) Microbiologyopen. 2022 Feb;11(1):e1260. (PMID: 35212478) Gut. 2020 Nov;69(11):2059-2060. (PMID: 32111633) Infection. 2012 Feb;40(1):63-7. (PMID: 21773761) Acta Oncol. 2009;48(1):27-33. (PMID: 18767000) Gut Microbes. 2018 Nov 2;9(6):559-566. (PMID: 29533125) Methods Mol Biol. 2011;675:215-20. (PMID: 20949391) Dis Colon Rectum. 2016 Mar;59(3):236-44. (PMID: 26855399) Sci Transl Med. 2015 May 6;7(286):286ra68. (PMID: 25947163) Cancer Med. 2022 Oct;11(20):3863-3872. (PMID: 35488387) BMC Palliat Care. 2015 Jan 20;14:2. (PMID: 25674038) Cancer Med. 2021 Aug;10(15):5041-5050. (PMID: 34250759) Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18321-6. (PMID: 25489084) Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9. (PMID: 17252614) Scand J Public Health. 2016 May;44(3):264-73. (PMID: 26647097) Gut. 2016 Nov;65(11):1906-1915. (PMID: 27531828) Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. (PMID: 31455888) JAMA Surg. 2021 Sep 1;156(9):865-874. (PMID: 34190968) BMJ. 2019 Mar 14;364:l803. (PMID: 30872356) Eur J Epidemiol. 2017 Sep;32(9):765-773. (PMID: 28983736) Int J Colorectal Dis. 2020 Jul;35(7):1211-1219. (PMID: 32306074) BMJ Open Gastroenterol. 2021 Jun;8(1):. (PMID: 34083227) Crit Rev Oncol Hematol. 2020 May;149:102909. (PMID: 32146284) J Clin Med. 2020 May 13;9(5):. (PMID: 32414103) Eur J Epidemiol. 2019 Apr;34(4):423-437. (PMID: 30929112) Int J Oncol. 2018 May;52(5):1727-1737. (PMID: 29532860) BMC Psychol. 2013 Nov 22;1(1):24. (PMID: 25566372) Nat Rev Microbiol. 2014 Oct;12(10):661-72. (PMID: 25198138) Clin Infect Dis. 2022 Nov 14;75(10):1747-1753. (PMID: 35380653) Acta Oncol. 2018 Dec;57(12):1611-1621. (PMID: 30477372) Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):43-54. (PMID: 27729657) J Lipid Res. 2013 Sep;54(9):2325-40. (PMID: 23821742) Pharmacol Res. 2011 Feb;63(2):146-50. (PMID: 21093590) Eur J Epidemiol. 2016 Feb;31(2):125-36. (PMID: 26769609) Clin Transl Gastroenterol. 2016 Nov 3;7(11):e200. (PMID: 27811909) J Natl Cancer Inst. 2022 Jan 11;114(1):1-2. (PMID: 34467390) J Med Screen. 2014 Sep;21(3):144-50. (PMID: 25070434) BMJ Open. 2013 May 03;3(5):. (PMID: 23645921) PLoS One. 2019 Sep 10;14(9):e0221964. (PMID: 31504043) Eur J Cancer. 2020 May;131:9-15. (PMID: 32248073) Clin Transl Oncol. 2020 Sep;22(9):1651-1656. (PMID: 32008218) Clin Epidemiol. 2021 Jan 12;13:21-41. (PMID: 33469380) Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35. (PMID: 16897791) |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) |
| تواريخ الأحداث: | Date Created: 20230725 Date Completed: 20231005 Latest Revision: 20231017 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10543975 |
| DOI: | 10.1158/1055-9965.EPI-23-0340 |
| PMID: | 37490284 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-7755 |
|---|---|
| DOI: | 10.1158/1055-9965.EPI-23-0340 |